Pestalozzi advises Cilag Holding AG on the USD 2.3 billion cash tender offer for Crucell NV
Johnson & Johnson, through its affiliate Cilag Holding AG, and Crucell NV acquired all outstanding equity of Crucell that it does not already own. Crucell is a global biopharmaceutica company focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Pestalozzi acted as advisor to Johnson & Johnson and Cilag.